Sarepta (SRPT) Sees Early Weakness, At-the-Market Offering In Focus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech stocks weigh on Wall Street as Iran stalemate lifts oil, yields
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- U.S. EV market shows signs of bottoming out: Bernstein
Sarepta Therapeutics (SRPT) Enters $40M At-The-Market Agreement with Citadel
September 4, 2012 5:07 PM EDTSarepta Therapeutics, Inc. (NASDAQ:... More
Sarepta Therapeutics (SRPT) Riding High On Successful Drug
August 30, 2012 8:08 AM EDTSarepta Therapeutics, Inc. (Nasdaq: SRPT) is higher yet again in pre-open trading Thursday as the company's Duchenne Muscular Dystrophy treatment continues to get positive,... More
